Regeneron is down 31.4% since the beginning of the year, and at $490.50 per share, it is trading 59.2% below its 52-week high of $1,202 from August 2024. Investors who bought $1,000 worth of ...

Through the deal, Regeneron says it aims to bolster its capabilities in genomics-driven drug discovery by integrating 23andMe's trove of over 15 million customer DNA profiles, collected via its ...

STORY: Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy.It also promised to prioritize the ethical use of customers ...

(Reuters) -Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from ...

Biotechnology company Regeneron buying 23andMe for $256 million By: Michelle Chapman, The Associated Press Posted: 8:00 AM CDT Monday, May. 19, 2025 Last Modified: 8:44 AM CDT Monday, May. 19, 2025 ...

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied ...